<DOC>
	<DOCNO>NCT00932763</DOCNO>
	<brief_summary>- Objective : - The objective study assess relative bioavailability two formulation immediate release amlodipine 10 mg fast condition , healthy subject . - Study Design : - This open-label , single-dose , 2-treatment , 2-period , randomize , crossover study.Twenty-two healthy subject enrol . Subjects successfully complete screen process check research center night first dose . Subjects continue meet inclusion/exclusion criterion morning dose assign subject number , base order successfully complete screen process procedure outline study protocol . Subjects randomly assign treatment sequence receive two separate single-dose administration study medication , one treatment per period , accord randomization schedule . Dosing day separate washout period least 14 day . Subjects receive treatment list two treatment period follow overnight fast least 10 hour : amlodipine Torrent Pharmaceuticals Ltd. Norvasc Pfizer , Inc .</brief_summary>
	<brief_title>Study Evaluate Bioavailability Test Formulation Amlodipine 10 mg Tablets ( Torrent Pharmaceuticals Limited ) Compared 10 mg Dose NorvascÂ® ( Pfizer ) 22 Fasted , Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Sex : Male/Female Age : 18 45 year . Volunteer BMI 1827 kg/m2 minimum 50 kg weight . Volunteers minimum blood pressure 110/75 mmHg . Healthy willing participate study . Signed Written Informed Consent Screening study . Medical case history , physical examination , vital sign , laboratory test ECG without significant deviation . Negative drug abuse screen test . Nonsmokers smoke less 10 cigarette day willing refrain smoking throughout course study . No history medication , prescription OTC , least 2 week prior study drug administration study Period II completion . Clinically relevant abnormal physical finding screen examination , would interfere objective study . Clinically relevant abnormality result laboratory screening evaluation . Clinically relevant ECG abnormality . Habituation tobacco necessitate uninterrupted tobacco consumption . Addiction alcohol history drug abuse . History kidney liver dysfunction . History allergy test drug drug chemically similar drug investigation . Administration/Intake prescription OTC medication two week study . Patients suffer chronic illness arthritis , asthma etc . HIV , HCV , HBsAg positive volunteer . Positive test drug abuse screen . Subjects suffer psychiatric ( acute chronic ) illness . Administration investigational drug period 0 30 day entry study . Intake barbiturates enzymeinducing drug last three month . History significant blood loss due reason , include blood donation past 12 week . The total blood loss last 3 month include anticipated blood loss study exceed 1000 ml . History bleed disorder . Existence surgical medical condition , , judgement clinical investigator , might interfere absorption , distribution , metabolism excretion drug likely compromise safety volunteer . Serious adverse reaction hypersensitivity study drug excipients . Inability communicate cooperate investigator due language problem , poor mental development impair cerebral function . Pregnant nursing mother . Female , unless surgically sterile least 2 year postmenopausal , practice barrier contraceptive method . Contraindications active inactive ingredient formulation . Subject willing able remain study unit entire duration confinement period return outpatient visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>